Jennifer L. Kuntz, PhD

Areas of Focus

 

Biography

Jennifer Kuntz, PhD, is a pharmacoepidemiologist and infectious disease epidemiologist. Her research answers questions about the safety and effectiveness of medication use and strategies that improve the way medications are used in clinical practice. She also has particular expertise in the study of health care-associated infections, most notably Clostridium difficile infection. Her research is driven by training and experience in study design, statistical methods, and the use of electronic health record data to conduct epidemiologic, health services, and outcomes research. Dr. Kuntz is currently building a research agenda focused on improving medication prescribing and use among older patients.

Dr. Kuntz joined CHR in 2010. She received her MS and PhD in epidemiology from the University of Iowa’s College of Public Health.

Selected Publications

 
  • Kuntz J, Kouch L, Christian D, Peterson PL, Gruss I. Barriers and Facilitators to the Deprescribing of Nonbenzodiazepine Sedative Medications Among Older Adults. Perm J. 2017 Apr 20;22. doi: 10.7812/TPP/17-157.
  • Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, McGlynn EA, Gozansky WS. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. J Bone Miner Res. 2018 Mar 12. doi: 10.1002/jbmr.3420. PMID: 29529334
  • Kuntz JL, Safford MM, Singh JA, Phansalkar S, Slight SP, Her QL, Lapointe NA, Mathews R, O'Brien E, Brinkman WB, Hommel K, Farmer KC, Klinger E, Maniam N, Sobko HJ, Bailey SC, Cho I, Rumptz MH, Vandermeer ML, Hornbrook MC. Patient-centered interventions to improve medication management and adherence: a qualitative review of research findings. Patient Educ Couns. 2014 Dec;97(3):310-26. doi: 10.1016/j.pec.2014.08.021 PMID: 25264309
  • Carnahan RM, Kuntz JL, Wang SV, Fuller C, Gagne JJ, Leonard CE, Hennessy S, Meyer T, Archdeacon P, Chen CY, Panozzo CA, Toh S, Katcoff H, Woodworth T, Iyer A, Axtman S, Chrischilles EA. Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clostridium difficile infection. Pharmacoepidemiol Drug Saf. 2018 Mar 13. doi: 10.1002/pds.4420. PMID: 29532543
  • Davis RL, Gallagher MA, Asgari MM, Eide MJ, Margolis DJ, Macy E, Burmester JK, Selvam N, Boscarino JA, Cromwell LF, Feigelson HS, Kuntz JL, Pawloski PA, Penfold RB, Raebel MA, Sridhar G, Wu A, La Grenade LA, Pacanowski MA, Pinheiro SP. Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):684-92. doi: 10.1002/pds.3778. PMID: 25914229
  • Kuntz JL, Johnson ES, Raebel MA, Platt RW, Petrik AF, Yang X, Thorp ML, Spindel SJ, Neil N, Smith DH. Predicting the risk of Clostridium difficile infection following an outpatient visit: development and external validation of a pragmatic, prognostic risk score. Clin Microbiol Infect. 2015 Mar;21(3):256-62. doi: 10.1016/j.cmi.2014.11.001. PMID: 25658533
  • Kuntz JL, Polgreen PM. The importance of considering different healthcare settings when estimating the burden of Clostridium difficile. Clin Infect Dis. 2015 Mar 15;60(6):831-6. doi: 10.1093/cid/ciu955. Epub 2014 Dec 4. PMID: 25477426
  • Kuntz JL, Johnson ES, Raebel MA, Petrik AF, Yang X, Thorp ML, Spindel SJ, Neil N, Smith DH. Epidemiology and healthcare costs of incident Clostridium difficile infections identified in the outpatient healthcare setting. Infect Control Hosp Epidemiol. 2012 Oct;33(10):1031-8. doi: 10.1086/667733. Epub 2012 Aug 23. PMID: 22961023
  • Kuntz JL, Baker JM, Kipnis P, Li SX, Liu V, Xie Y, Marcella S, Escobar GJ. Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study. Infect Control Hosp Epidemiol. 2017 Jan;38(1):45-52. doi: 10.1017/ice.2016.232. PMID: 27760583

Press Release

Researchers and Pharmacists Team Up to Combat Opioid Overuse

Scientists at the Center for Health Research recently partnered with KP pharmacists to test a program to curb prolonged opioid use, as part of an FDA-funded clinical trial.

May 04, 2017